Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
MAYNE PHARMA GROUP LIMITED (MYX)ASX AI Signals has generated 0 signals for MYX during the last 90 days, indicating low trading activity
MYX Share Price | |
| Current Price | $2.760 |
| 52 Week High | $6.300 |
| 52 Week Low: | $2.130 |
| Trading at (% of 52 Week High) | 43.81% |
Mayne Pharma Group Limited (ASX: MYX) is a pharmaceutical company that develops, manufactures, and sells generic and specialty pharmaceutical products. The company focuses on delivering high-quality medicines in areas such as dermatology, pain management, and women's health. Mayne Pharma serves markets primarily in the United States, Australia, and New Zealand.
The Pharmaceuticals, Biotechnology & Life Sciences sector on the ASX includes companies involved in the development, production, and commercialization of drugs, medical devices, and biotechnology products. This sector covers activities such as research and development of new medicines, genetic testing, and innovative healthcare technologies. Companies often work on treatments for diseases, including cancer, infectious diseases, and chronic conditions. The sector plays a crucial role in advancing medical science and improving patient care through innovation.
Mayne Pharma Group Limited CEO Aaron Gray talked with Jonathan Jackson from Proactive at the Small and Mid-Cap Conference about the company’s strategy, product portfolio, and recent H1 results, highlighting its focus on women’s health and dermatology markets in the United States.
Gray explained ADELAIDE, Australia, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Mayne Pharma Group Limited (ASX: MYX) today announced that Shawn Patrick O’Brien, Chief Executive Officer of Mayne Pharma, will present at the 42nd Annual J.P. Morgan Healthcare Conference as follows:
Date: Thursday, January 11, 2024 Time: 7: Key Insights
Mayne Pharma Group's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 23 investors have a majority stake in the company with 50% ownership Insiders have bought recently
To get a sense of who is trul Even if it's not a huge purchase, we think it was good to see that Shawn O’Brien, the CEO, MD & Director of Mayne Pharma Group Limited (ASX:MYX) recently shelled out AU$141k to buy stock, at AU$3.80 per share. Nevertheless, it only increased their shareholding by a minuscule percentage, and it was This week we saw the Mayne Pharma Group Limited (ASX:MYX) share price climb by 10%. But spare a thought for the long term holders, who have held the stock as it bled value over the last five years. Five years have seen the share price descend precipitously, down a full 84%. It's true that the recentLatest MAYNE PHARMA GROUP LIMITED(MYX) News
Mayne Pharma growth strategy in Women’s health - ASX SMIDcaps Conference
Mayne Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
While institutions invested in Mayne Pharma Group Limited (ASX:MYX) benefited from last week's 12% gain, retail investors stood to gain the most
Shawn O’Brien Buys Handful Of Shares In Mayne Pharma Group
Strong week for Mayne Pharma Group (ASX:MYX) shareholders doesn't alleviate pain of five-year loss
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial